A survey of medical cannabis use during perimenopause and postmenopause DOI Creative Commons
Mary Kathryn Dahlgren, Celine El-Abboud, Ashley M. Lambros

et al.

Menopause The Journal of The North American Menopause Society, Journal Year: 2022, Volume and Issue: 29(9), P. 1028 - 1036

Published: Aug. 2, 2022

Abstract Objective Expanding access to legal cannabis has dovetailed with increased interest in medical (MC) use; however, there is a paucity of research examining MC use alleviate menopause-related symptoms. This survey study assessed patterns perimenopausal and postmenopausal individuals. Methods Participants (perimenopausal, n = 131; postmenopausal, 127) completed assessments symptomatology use, including modes type symptoms addressed by use. Results Most participants reported current (86.1%) endorsed using for (78.7%). The most common were smoking (84.3%) edibles (78.3%), the top sleep disturbance (67.4%) mood/anxiety (46.1%). Relative participants, significantly worse on vasomotor psychosocial subscales Menopause-Specific Quality Life Questionnaire ( P s ≤ 0.04), greater burden anxiety 0.01) hot flash 0.04) In addition, higher incidence depression 0.03) diagnoses < 0.01), as well treat relative 0.01). Conclusions suggest that many individuals are currently an adjunctive treatment symptoms, particularly mood/anxiety. Future should examine impact different characteristics (e.g., cannabinoid profiles) efficacy Increased severity prevalence mood promising targets clinical trials cannabinoid-based therapies.

Language: Английский

Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada DOI Creative Commons
Janni Leung, Gary Chan, Daniel Stjepanović

et al.

Psychopharmacology, Journal Year: 2022, Volume and Issue: 239(5), P. 1509 - 1519

Published: Jan. 12, 2022

There has been increasing attention on cannabis use for medical purposes, but there is currently a lack of data its epidemiology.To examine the epidemiology self-reported purposes by (1) estimating prevalence, (2) comparing gender and age differences, (3) investigating what reasons they were used to manage.Participants included 27,169 respondents (aged 16-65) who completed Wave 1 The International Cannabis Policy Study (ICPS) conducted across Canada USA in 2018 via online surveys. policy conditions "US legal-recreational" (legal both recreational uses), legal-medical only", illegal", "Canada-medical only".The overall prevalence ever was 27%, with similar rates sex highest young adults. Prevalence higher US legal-recreational states (34%) than illegal (23%), only (25%), (25%). most common physical health include manage pain (53%), sleep (46%), headaches/migraines (35%), appetite (22%), nausea/vomiting (21%). For mental reasons, anxiety (52%), depression (40%), PTSD/trauma (17%). 11% reported using managing other drug or alcohol 4% psychosis.A substantial proportion North American population variety including those living jurisdictions without legal markets. Further research needed understand safety efficacy these forms use.

Language: Английский

Citations

87
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review DOI Open Access
Deborah S. Hasin, Claire Walsh

Journal of Clinical Medicine, Journal Year: 2020, Volume and Issue: 10(1), P. 15 - 15

Published: Dec. 23, 2020

Background: The landscape of attitudes, legal status and patterns use cannabis is rapidly changing in the United States elsewhere. Therefore, primary aim this narrative review to provide a concise overview literature on comorbidity disorder (CUD) with other substance psychiatric disorders, information accurately guide future directions for field. Methods: A PubMed was conducted studies relating use, CUD, co-occurring disorder. To an representative data, focused national-level, population-based work from National Epidemiologic Survey Alcohol Related Conditions (NESARC) Drug Use Health (NSDUH) surveys. Considering laws, recent (past five-year) were addressed. Results: strong body shows associations between CUD drug psychosis, mood anxiety personality disorders. strongest evidence potential causal relationship exists psychotic While some directionality results are inconsistent. Studies have established higher rates among those but little about specifics understood. Conclusions: Although general population increasingly perceives be harmless substance, empirical that associated both comorbid illness. However, there mixed regarding role etiology, course, prognosis across all categories Future research should expand existing representative, longitudinal order better understand acute long-term effects

Language: Английский

Citations

87
Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis DOI Creative Commons
Tory R. Spindle, C. Austin Zamarripa, Ethan B. Russo

et al.

Drug and Alcohol Dependence, Journal Year: 2024, Volume and Issue: 257, P. 111267 - 111267

Published: March 13, 2024

Language: Английский

Citations

12
PTSD, distress and substance use in the aftermath of October 7th, 2023, terror attacks in Southern Israel DOI
Daniel L. Feingold, Yuval Neria, Dana Tzur Bitan

et al.

Journal of Psychiatric Research, Journal Year: 2024, Volume and Issue: 174, P. 153 - 158

Published: April 13, 2024

Language: Английский

Citations

12
Development of cannabidiol derivatives as potent broad-spectrum antibacterial agents with membrane-disruptive mechanism DOI

Shanfang Fang,

Wen-Tyng Kang,

Haizhou Li

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 266, P. 116149 - 116149

Published: Jan. 17, 2024

Language: Английский

Citations

10
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors DOI
Kelly A. Sagar, Staci A. Gruber

CNS Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

Citations

1
Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry DOI Creative Commons
Raphael Rifkin‐Zybutz, Simon Erridge,

Carl Holvey

et al.

Psychopharmacology, Journal Year: 2023, Volume and Issue: 240(8), P. 1735 - 1745

Published: June 14, 2023

Abstract Rationale Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence their effectiveness and safety. Objectives This study aimed to evaluate the clinical outcomes patients with GAD treated dried flower, oil-based preparations, or combination both CBMPs. Methods A prospective cohort ( n = 302) enrolled in UK Medical Cannabis Registry prescribed oil flower-based CBMPs was performed. Primary were changes disorder-7 (GAD-7) questionnaires at 1, 3, 6 months compared baseline. Secondary single-item sleep quality scale (SQS) health-related life index (EQ-5D-5L) same time points. These assessed by paired t -tests. Adverse events line CTCAE (Common Terminology Criteria Events) v4.0. Results Improvements anxiety, observed each point p < 0.001). Patients receiving had improvements GAD-7 all points (1 month: difference −5.3 (95% CI −4.6 −6.1), 3 months: −5.5 −4.7 −6.4), −4.5 −3.2 −5.7)). Thirty-nine participants (12.9%) reported 269 adverse follow-up period. Conclusions Prescription those associated clinically significant an acceptable safety profile real-world setting. Randomised trials are required next step investigate efficacy

Language: Английский

Citations

20
Effects of inhaled cannabis high in Δ9-THC or CBD on the aging brain: A translational MRI and behavioral study DOI Creative Commons
Aymen H. Sadaka,

Justin Canuel,

Marcelo Febo

et al.

Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15

Published: Feb. 1, 2023

With the recent legalization of inhaled cannabis for medicinal and recreational use, elderly represents one newest, rapidly growing cohorts users. To understand neurobiological effects on aging brain, 19–20 months old mice were divided into three groups exposed to vaporized containing ~10% Δ9-THC, CBD, or placebo 30 min each day. Voxel based morphometry, diffusion weighted imaging, resting state functional connectivity data gathered after 28 days exposure following a two-week washout period. Tail-flick, open field, novel object preference tests conducted explore analgesic, anxiolytic, cognitive cannabis, respectively. Vaporized high in Δ9-THC CBD achieved blood levels reported human Mice showed antinociceptive chronic without tolerance while anxiolytic waned with treatment. had no effect any behavioral measures. morphometry decrease midbrain dopaminergic volume followed but an increase washout. Fractional anisotropy values reduced same area by suggesting reduction gray matter volume. Cannabis not THC increased network strength efficiency, that persisted These would indicate use can be effective analgesic treatment anxiety decline. The system was sensitive showing robust plasticity water diffusivity prior drug cessation possibly related abuse liability Δ9-THC. Chronic resulted enhanced global cessation. consequences this sustained change brain remain determined.

Language: Английский

Citations

19
Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression DOI

Giulia De Feo,

Amy A. Case, Gregory B. Crawford

et al.

Supportive Care in Cancer, Journal Year: 2023, Volume and Issue: 31(3)

Published: Feb. 21, 2023

Language: Английский

Citations

19
Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study DOI Creative Commons

Lara Bapir,

Simon Erridge,

Martha Nicholas

et al.

Expert Review of Neurotherapeutics, Journal Year: 2023, Volume and Issue: 23(3), P. 281 - 295

Published: Feb. 20, 2023

There is growing evidence on the efficacy of cannabis-based medicinal products (CBMPs) for chronic pain (CP). Due to interaction between CP and anxiety, potential impact CBMPs both anxiety CP, this article aimed compare outcomes patients with without co-morbid following CBMP treatment.Participants were prospectively enrolled categorized by baseline General Anxiety Disorder-7(GAD-7) scores, into 'no anxiety'(GAD-7 < 5) 'anxiety'(GAD-7 ≥ cohorts. Primary changes in Brief Pain Inventory Short-Form, Short-form McGill Questionnaire-2, Visual Analogue Scale, Sleep Quality Scale (SQS), GAD-7 EQ-5D-5L index values at 1, 3 6 months.1254 (anxiety = 711; no 543) met inclusion criteria. Significant improvements all primary observed timepoints (p 0.050), except group(p > 0.050). The cohort reported greater values, SQS GAD-7(p but there consistent differences outcomes.A association health-related quality life (HRQoL) was identified. Those HRQoL.

Language: Английский

Citations

18